Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Capital Expenditures: 2024-2025

Historic Capital Expenditures for Silence Therapeutics (SLN) over the last 2 years, with Sep 2025 value amounting to $3,000.

  • Silence Therapeutics' Capital Expenditures fell 95.31% to $3,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $59,000, marking a year-over-year decrease of 60.40%. This contributed to the annual value of $211,000 for FY2024, which is 276.79% up from last year.
  • Silence Therapeutics' Capital Expenditures amounted to $3,000 in Q3 2025, which was down 93.75% from $48,000 recorded in Q2 2025.
  • Silence Therapeutics' Capital Expenditures' 5-year high stood at $85,000 during Q2 2024, with a 5-year trough of $3,000 in Q3 2025.